Net margin is calculated as Net Income divided by its Revenue. Tarsus Pharmaceuticals's Net Income for the
three
months ended in Dec. 2023 was $-41.90 Mil. Tarsus Pharmaceuticals's Revenue for the
three
months ended in Dec. 2023 was $13.08 Mil. Therefore, Tarsus Pharmaceuticals's net margin for the quarter that ended in Dec. 2023 was -320.45%.
The historical rank and industry rank for Tarsus Pharmaceuticals's Net Margin % or its related term are showing as below:
TARS'
s Net Margin % Range Over the Past 10 Years
Min: -778.89 Med: -240.51 Max: -24.25
Current: -778.89
TARS's Net Margin % is ranked worse than 69.98% of 1026
companies
in the Biotechnology industry
Industry Median: -163.08
vs TARS: -778.89
Tarsus Pharmaceuticals Net Margin % Historical Data
The historical data trend for Tarsus Pharmaceuticals's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Tarsus Pharmaceuticals's Net Margin %
For the Biotechnology subindustry, Tarsus Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsus Pharmaceuticals's Net Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's Net Margin % falls into.
Tarsus Pharmaceuticals Net Margin % Calculation
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Tarsus Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals (NAS:TARS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Tarsus Pharmaceuticals Net Margin % Related Terms
Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Tarsus Pharmaceuticals (Tarsus Pharmaceuticals) Business Description
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03 is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TARS has been successfully added to your 